<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Repligen Corporation — News on 6ix</title>
    <link>https://6ix.com/company/repligen-corporation</link>
    <description>Latest news and press releases for Repligen Corporation on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 22 Apr 2026 11:30:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/repligen-corporation" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835b77b78dffbe2df1148dc.webp</url>
      <title>Repligen Corporation</title>
      <link>https://6ix.com/company/repligen-corporation</link>
    </image>
    <item>
      <title>Repligen to Report First Quarter 2026 Financial Results</title>
      <link>https://6ix.com/company/repligen-corporation/news/repligen-to-report-first-quarter-2026-financial-results-1</link>
      <guid isPermaLink="true">https://6ix.com/company/repligen-corporation/news/repligen-to-report-first-quarter-2026-financial-results-1</guid>
      <pubDate>Wed, 22 Apr 2026 11:30:00 GMT</pubDate>
      <description>Webcast and Conference Call to Be Held Tuesday, May 5, 2026, at 8:00 a.m. ETWALTHAM, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2026 financial results on Tuesday, May 5, 2026. The Company will issue a press release before the market opens and will host a conference call at 8:00 a.m. ET to discuss business updates and financial results for the three-month reporting period ended March 31, 2026. The con</description>
    </item>
    <item>
      <title>908 Devices Appoints Kola Otitoju as Chief Business &amp; Strategy Officer and Announces an Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)</title>
      <link>https://6ix.com/company/repligen-corporation/news/908-devices-appoints-kola-otitoju-as-chief-business-and-strategy-officer-and-announces-an-inducement-grant-under-nasdaq-listing-rule-5635c4-22</link>
      <guid isPermaLink="true">https://6ix.com/company/repligen-corporation/news/908-devices-appoints-kola-otitoju-as-chief-business-and-strategy-officer-and-announces-an-inducement-grant-under-nasdaq-listing-rule-5635c4-22</guid>
      <pubDate>Tue, 21 Apr 2026 21:00:00 GMT</pubDate>
      <description>BURLINGTON, Mass., April 21, 2026--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces the appointment of Kola Otitoju as its Chief Business &amp; Strategy Officer, a newly created executive position. Mr. Otitoju will oversee product and corporate strategy, business development, mergers and acquisitions, and partnership initiatives as 908 Devices expands its market presence across public health, safety, and defense-tech applications.</description>
    </item>
    <item>
      <title>Repligen Opens European Training &amp; Innovation Center in Breda, Expanding Global Customer Support Network</title>
      <link>https://6ix.com/company/repligen-corporation/news/repligen-opens-european-training-and-innovation-center-in-breda-expanding-global-customer-support-network</link>
      <guid isPermaLink="true">https://6ix.com/company/repligen-corporation/news/repligen-opens-european-training-and-innovation-center-in-breda-expanding-global-customer-support-network</guid>
      <pubDate>Fri, 17 Apr 2026 11:30:00 GMT</pubDate>
      <description>WALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the grand opening of its new Repligen Training &amp; Innovation Center (“RTIC”) at its OPUS® Pre-packed Chromatography Columns manufacturing facility in Breda, the Netherlands. The RTIC buildout, which features product exhibits and purpose-built demonstration areas, was designed to provide customers with pre- and post-sales sup</description>
    </item>
    <item>
      <title>Repligen Corporation to Present at Upcoming March Conferences</title>
      <link>https://6ix.com/company/repligen-corporation/news/repligen-corporation-to-present-at-upcoming-march-conferences-9</link>
      <guid isPermaLink="true">https://6ix.com/company/repligen-corporation/news/repligen-corporation-to-present-at-upcoming-march-conferences-9</guid>
      <pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
      <description>WALTHAM, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership,</description>
    </item>
    <item>
      <title>Repligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance</title>
      <link>https://6ix.com/company/repligen-corporation/news/repligen-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-2026-financial-guidance</link>
      <guid isPermaLink="true">https://6ix.com/company/repligen-corporation/news/repligen-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-2026-financial-guidance</guid>
      <pubDate>Tue, 24 Feb 2026 12:30:00 GMT</pubDate>
      <description>Fourth quarter revenue of $198 million, a year-over-year increase of 18% as reported, 14% organic with continued momentum in orders in the quarterFull year 2025 revenue of $738 million, a year-over-year increase of 16% for both reported and organic non-COVIDFull year 2026 revenue guidance of $810 million - $840 million, 10% to 14% reported revenue growth, 9% to 13% organic and adjusted operating margin expansion of 150 bps at the midpoint WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Replige</description>
    </item>
    <item>
      <title>Repligen to Report Fourth Quarter and Full Year 2025 Financial Results</title>
      <link>https://6ix.com/company/repligen-corporation/news/repligen-report-fourth-quarter-full-123000262</link>
      <guid isPermaLink="true">https://6ix.com/company/repligen-corporation/news/repligen-report-fourth-quarter-full-123000262</guid>
      <pubDate>Tue, 10 Feb 2026 12:30:00 GMT</pubDate>
      <description>Webcast and Conference Call to Be Held Tuesday, February 24, 2026, at 8:30 a.m. ETWALTHAM, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter 2025 financial results on Tuesday, February 24, 2026. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- and twelve- month reporting periods end</description>
    </item>
    <item>
      <title>Repligen Executive Chair Tony Hunt to Retire; Dr. Martin D. Madaus Elected Chair</title>
      <link>https://6ix.com/company/repligen-corporation/news/repligen-executive-chair-tony-hunt-123000093</link>
      <guid isPermaLink="true">https://6ix.com/company/repligen-corporation/news/repligen-executive-chair-tony-hunt-123000093</guid>
      <pubDate>Tue, 06 Jan 2026 12:30:00 GMT</pubDate>
      <description>WALTHAM, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership,...</description>
    </item>
    <item>
      <title>Repligen Corporation to Present at J.P. Morgan 2026 Healthcare Conference</title>
      <link>https://6ix.com/company/repligen-corporation/news/repligen-corporation-present-jp-morgan-2026-healthcare-conference-2025-12-18</link>
      <guid isPermaLink="true">https://6ix.com/company/repligen-corporation/news/repligen-corporation-present-jp-morgan-2026-healthcare-conference-2025-12-18</guid>
      <pubDate>Thu, 18 Dec 2025 05:00:00 GMT</pubDate>
      <description>WALTHAM, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership,</description>
    </item>
    <item>
      <title>Repligen Introduces Next-Generation Chromatography Resins to Advance New Modality Workflows</title>
      <link>https://6ix.com/company/repligen-corporation/news/repligen-introduces-next-generation-chromatography-resins-advance-new-modality</link>
      <guid isPermaLink="true">https://6ix.com/company/repligen-corporation/news/repligen-introduces-next-generation-chromatography-resins-advance-new-modality</guid>
      <pubDate>Tue, 16 Dec 2025 05:00:00 GMT</pubDate>
      <description>WALTHAM, Mass., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership,</description>
    </item>
    <item>
      <title>Repligen Corporation to Present at Evercore Healthcare Conference</title>
      <link>https://6ix.com/company/repligen-corporation/news/repligen-corporation-present-evercore-healthcare-conference-2025-11-26</link>
      <guid isPermaLink="true">https://6ix.com/company/repligen-corporation/news/repligen-corporation-present-evercore-healthcare-conference-2025-11-26</guid>
      <pubDate>Wed, 26 Nov 2025 05:00:00 GMT</pubDate>
      <description>WALTHAM, Mass., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership,</description>
    </item>
    <item>
      <title>Repligen Corporation to Present at Upcoming November Conferences</title>
      <link>https://6ix.com/company/repligen-corporation/news/repligen-corporation-present-upcoming-november-conferences-2025-11-04</link>
      <guid isPermaLink="true">https://6ix.com/company/repligen-corporation/news/repligen-corporation-present-upcoming-november-conferences-2025-11-04</guid>
      <pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
      <description>WALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership,</description>
    </item>
    <item>
      <title>Repligen Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance</title>
      <link>https://6ix.com/company/repligen-corporation/news/repligen-reports-third-quarter-2025-financial-results-and-updates-full-year-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/repligen-corporation/news/repligen-reports-third-quarter-2025-financial-results-and-updates-full-year-2025</guid>
      <pubDate>Tue, 28 Oct 2025 04:00:00 GMT</pubDate>
      <description>Revenue of $189 million, year-over-year increase of 22% as reported and 18% organic with double-digit reported growth across all franchisesOrders increased</description>
    </item>
    <item>
      <title>Repligen to Report Third Quarter 2025 Financial Results</title>
      <link>https://6ix.com/company/repligen-corporation/news/repligen-report-third-quarter-2025-financial-results-2025-10-15</link>
      <guid isPermaLink="true">https://6ix.com/company/repligen-corporation/news/repligen-report-third-quarter-2025-financial-results-2025-10-15</guid>
      <pubDate>Wed, 15 Oct 2025 04:00:00 GMT</pubDate>
      <description>Webcast and Conference Call to Be Held Tuesday, October 28, 2025, at 8:30 a.m. ET WALTHAM, Mass., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation</description>
    </item>
    <item>
      <title>Repligen Corporation to Present at Upcoming September Conferences</title>
      <link>https://6ix.com/company/repligen-corporation/news/repligen-corporation-present-upcoming-september-conferences-2025-08-22</link>
      <guid isPermaLink="true">https://6ix.com/company/repligen-corporation/news/repligen-corporation-present-upcoming-september-conferences-2025-08-22</guid>
      <pubDate>Fri, 22 Aug 2025 04:00:00 GMT</pubDate>
      <description>WALTHAM, Mass., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership,</description>
    </item>
    <item>
      <title>Repligen Announces Strategic Partnership with Novasign to Further Advance Bioprocessing Digitalization</title>
      <link>https://6ix.com/company/repligen-corporation/news/repligen-announces-strategic-partnership-novasign-further-advance-bioprocessing</link>
      <guid isPermaLink="true">https://6ix.com/company/repligen-corporation/news/repligen-announces-strategic-partnership-novasign-further-advance-bioprocessing</guid>
      <pubDate>Thu, 31 Jul 2025 04:00:00 GMT</pubDate>
      <description>WALTHAM, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership,</description>
    </item>
    <item>
      <title>Repligen Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance</title>
      <link>https://6ix.com/company/repligen-corporation/news/repligen-reports-second-quarter-2025-financial-results-and-updates-full-year-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/repligen-corporation/news/repligen-reports-second-quarter-2025-financial-results-and-updates-full-year-2025</guid>
      <pubDate>Tue, 29 Jul 2025 04:00:00 GMT</pubDate>
      <description>Revenue of $182 million, year-over-year increase of 15% as reported and 17% organic non-COVID growthOrders grew sequentially and greater than 20%</description>
    </item>
    <item>
      <title>Repligen to Report Second Quarter 2025 Financial Results</title>
      <link>https://6ix.com/company/repligen-corporation/news/repligen-report-second-quarter-2025-financial-results-2025-07-17</link>
      <guid isPermaLink="true">https://6ix.com/company/repligen-corporation/news/repligen-report-second-quarter-2025-financial-results-2025-07-17</guid>
      <pubDate>Thu, 17 Jul 2025 04:00:00 GMT</pubDate>
      <description>Webcast and Conference Call to Be Held Tuesday, July 29, 2025, at 8:30 a.m. ET WALTHAM, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation</description>
    </item>
    <item>
      <title>908 Devices Appoints Christopher D. Brown to its Board of Directors</title>
      <link>https://6ix.com/company/repligen-corporation/news/908-devices-appoints-christopher-d-brown-its-board-directors-2025-06-16-1</link>
      <guid isPermaLink="true">https://6ix.com/company/repligen-corporation/news/908-devices-appoints-christopher-d-brown-its-board-directors-2025-06-16-1</guid>
      <pubDate>Mon, 16 Jun 2025 04:00:00 GMT</pubDate>
      <description>BOSTON--(BUSINESS WIRE)-- 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has appointed</description>
    </item>
    <item>
      <title>Repligen Announces Publication of the Company’s 2024 Corporate Sustainability Report</title>
      <link>https://6ix.com/company/repligen-corporation/news/repligen-announces-publication-companys-2024-corporate-sustainability-report-2025-05</link>
      <guid isPermaLink="true">https://6ix.com/company/repligen-corporation/news/repligen-announces-publication-companys-2024-corporate-sustainability-report-2025-05</guid>
      <pubDate>Tue, 27 May 2025 04:00:00 GMT</pubDate>
      <description>WALTHAM, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership,</description>
    </item>
    <item>
      <title>Repligen Corporation to Present at William Blair Growth Conference</title>
      <link>https://6ix.com/company/repligen-corporation/news/repligen-corporation-present-william-blair-growth-conference-2025-05-22</link>
      <guid isPermaLink="true">https://6ix.com/company/repligen-corporation/news/repligen-corporation-present-william-blair-growth-conference-2025-05-22</guid>
      <pubDate>Thu, 22 May 2025 04:00:00 GMT</pubDate>
      <description>WALTHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership,</description>
    </item>
  </channel>
</rss>